The COVID‐19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID‐19‐associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). SARS‐CoV‐2 vaccination may help reduce the morbidity and mortality of COVID‐19 among SOTR. Under emergency use authorization, the US Food Drug Administration approved two SARS‐CoV‐2 messenger RNA vaccines [BNT162b2 (Pfizer), mRNA‐1273 (Moderna)] and an adenovirus vector‐based vaccine [Ad26.COV2.S (Johnson and Johnson)].
Effectiveness of SARS‐CoV‐2 vaccination in fully‐vaccinated solid organ transplant recipients